SAGE - Sage TherapeuticsAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $43.73 | Open | |
| Volume | 1 | Market Cap | 2.581B |
| Yield | Last Dividend |
| Sage Therapeutics: Showing Upside, But T... | 07/25/21 |
| No summary available. | |
| Sage Therapeutics to Report Second Quart... | 07/20/21 |
| Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives | |
| Sage Therapeutics Needs To Show Improved... | 07/12/21 |
| No summary available. | |
| Essential Tremor Treatment Market Growth... | 07/09/21 |
| Essential Tremor Treatment Market analysis report is sure to help boost sales and improve return on investment (ROI). The research and analysis carrie... | |
| Sage Therapeutics to Participate in Cowe... | 07/08/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with th... | |
| Rapid-acting Sage Therapeutics and Bioge... | 06/25/21 |
| Sage Therapeutics and Biogen have recently announced positive results from a pivotal Phase III trial for their novel, GABA A receptor allosteric modul... | |
| How Sage Therapeutics Beaten-Down Stock ... | 06/21/21 |
| Jefferies analyst Andrew Tsai called the stocks swoon last week an overreaction. It should recover within the next three to six months, he said. | |
| What Happened to Sage Therapeutics Stock... | 06/21/21 |
| Sage has been struggling for some time to bring its flagship antidepressant to the market. | |
| Here''s Why Sage Therapeutics Tanked Thi... | 06/19/21 |
| The neuroscience-focused biotech company didn''t give investors the result they wanted. | |
| Sage Therapeutics: Should You Buy This B... | 06/17/21 |
| Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs o... | |
| SAGE Announces Positive Results for Zura... | 06/16/21 |
| Biopharmaceutical company Sage Therapeutics, Inc. (SAGE) and Biogen Inc. The post SAGE Announces Positive Results for Zuranolone; Shares Plunge 19.3% ... | |
| Analysts Conflicted on These Healthcare ... | 06/16/21 |
| Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE), Axsome Therapeutics (AXSM) and Morphosys ... | |
| Oppenheimer Stick to Their Buy Rating fo... | 06/15/21 |
| Oppenheimer Stick to Their Buy Rating for SAGE Therapeutics | |
| Here''s Why Sage Therapeutics Stock Is S... | 06/15/21 |
| Long-awaited clinical trial results weren''t as successful as hoped. | |
| DraftKings, Sage Therapeutics, Vroom and... | 06/15/21 |
| The post DraftKings, Sage Therapeutics, Vroom and more appeared on BitcoinEthereumNews.com . New England Patriots cornerback Stephon Gilmore (24) stre... | |
| Moving - Stocks making the biggest moves... | 06/15/21 |
| These are the stocks posting the largest moves in midday trading. | |
| Heres why Sage Therapeutics fell 18% on ... | 06/15/21 |
| Sage Therapeutics Inc (NASDAQ: SAGE) said on Tuesday its candidate drug for depression that it developed in collaboration with Biogen Inc was found ef... | |
| Sage Stock Tumbles As Analysts Question ... | 06/15/21 |
| The post Sage Stock Tumbles As Analysts Question Positive Depression Drug Study appeared on BitcoinEthereumNews.com . Sage Therapeutics (SAGE) unveile... | |
| Sage Stock Tumbles As Analysts Question ... | 06/15/21 |
| Sage Therapeutics unveiled "positive" results for its depression treatment Tuesday, but Sage stock tumbled. | |
| Why Sage is Dipping | 06/15/21 |
| Sage Therapeutics Inc (NASDAQ:SAGE), looking to make a comeback, revealed data from another Phase 3 evaluating zuranolone in patients with Major Depre... | |
| AstraZeneca antibody therapy failed to p... | 06/15/21 |
| Sage Therapeutics reported that an experimental pill designed to alleviate depression was successful in a large trial. | |
| Biogen says experimental drug for rare r... | 06/15/21 |
| Shares of Biogen Inc. were down 0.3% in premarket trading on Tuesday, the day after the company said an experimental gene therapy for choroideremia fa... | |
| Sages depression drug study results show... | 06/15/21 |
| Sage Therapeutics said on Tuesday its experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage stud... | |
| Mizuho Securities Stick to Their Hold Ra... | 06/15/21 |
| Mizuho Securities Stick to Their Hold Rating for SAGE Therapeutics | |
| Vroom, Ping Identity, Sage Therapeutics ... | 06/15/21 |
| The post Vroom, Ping Identity, Sage Therapeutics & more appeared on BitcoinEthereumNews.com . Take a look at some of the biggest movers in the premark... | |
| Stocks making the biggest moves in the p... | 06/15/21 |
| Take a look at some of the biggest movers in the premarket: Vroom (VRM) Vroom intends to offer $500 million in convertible senior notes due in 2026. ... | |
| Moving - Stocks making the biggest moves... | 06/15/21 |
| Names on the move ahead of the open. | |
| Stocks making the biggest moves in the p... | 06/15/21 |
| The stocks making the biggest moves in premarket trading include Vroom, Ping Identity, Sage Therapeutics, and more. | |
| Sage Therapeutics Plunges After Depressi... | 06/15/21 |
| Sage Therapeutics shares plunge following disappointing test results for its depression drug Zuranolone that it is producing with drug giant Biogen. | |
| Sage, Biogen Announce Positive Pivotal P... | 06/15/21 |
| WESTON (dpa-AFX) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced Tuesday that the WATERFALL Study in patients with Major Depressive ... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| FEAT. ANDRE 3000 | JOHN KROLIKOWSKI JR | 83.00 % | Follow |
| FEAT. MIGUEL | JOHN KROLIKOWSKI JR | 74.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
